Literature DB >> 2169357

Increase of Gi alpha in human hearts with dilated but not ischemic cardiomyopathy.

M Böhm1, P Gierschik, K H Jakobs, B Pieske, P Schnabel, M Ungerer, E Erdmann.   

Abstract

In myocardial membranes from hearts with dilated cardiomyopathy (DCM), there was a 37% increase of the Gi alpha-protein as measured by 32P-ADP-ribosylation of a approximately 40 kDa pertussis toxin substrate. Immunoblotting techniques also showed increased amounts of Gi alpha in DCM. In hearts with ischemic cardiomyopathy (ICM), Gi alpha was not altered compared with nonfailing myocardium (NF). Basal and Gpp(NH)p-stimulated adenylate cyclase activity was reduced in DCM but not in ICM. The number of beta-adrenoceptors was similarly reduced both in DCM and ICM compared with NF. Alterations of m-cholinoceptors or A1-adenosine receptors did not occur. Consistently, "indirect" negative inotropic effects of the m-cholinoceptor agonist carbachol and the A1-adenosine receptor agonist R-PIA were not different in ICM, DCM, and nonfailing myocardium. In ICM and DCM, there was a marked reduction of the positive inotropic responses to isoprenaline and milrinone. However, there was a further reduction in DCM compared with ICM. It is concluded that the increase of Gi alpha is accompanied by a reduction of basal and guanine-nucleotide-stimulated adenylate cyclase activity. Alterations of m-cholinoceptors and A1-adenosine receptors do not appear to be involved. The further decrease of the positive inotropic effects of isoprenaline and milrinone in DCM provides evidence that the increase of Gi alpha is functionally relevant in DCM but not ICM and hence might contribute to the reduced effects of endogenous catecholamines and exogenous cAMP-dependent positive inotropic agents in the former but not the latter condition.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2169357     DOI: 10.1161/01.cir.82.4.1249

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  59 in total

Review 1.  Transcriptional regulation by cAMP in the heart.

Authors:  F U Müller; J Neumann; W Schmitz
Journal:  Mol Cell Biochem       Date:  2000-09       Impact factor: 3.396

2.  Absence of the inhibitory G-protein Galphai2 predisposes to ventricular cardiac arrhythmia.

Authors:  Zia Zuberi; Muriel Nobles; Sonia Sebastian; Alex Dyson; Shiang Y Lim; Ross Breckenridge; Lutz Birnbaumer; Andrew Tinker
Journal:  Circ Arrhythm Electrophysiol       Date:  2010-05-21

3.  Crosstalk between Gi and Gq/Gs pathways in airway smooth muscle regulates bronchial contractility and relaxation.

Authors:  Dennis W McGraw; Jean M Elwing; Kevin M Fogel; Wayne C H Wang; Clare B Glinka; Kathryn A Mihlbachler; Marc E Rothenberg; Stephen B Liggett
Journal:  J Clin Invest       Date:  2007-04-05       Impact factor: 14.808

4.  Pathophysiology of heart failure.

Authors:  E Erdmann
Journal:  Heart       Date:  1998-06       Impact factor: 5.994

5.  Effects of propranolol treatment on left ventricular function and intracellular calcium regulation in rats with postinfarction heart failure.

Authors:  S E Litwin; S E Katz; J P Morgan; P S Douglas
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

Review 6.  Mutations of signal-transducing G proteins in human disease.

Authors:  P Schnabel; M Böhm
Journal:  J Mol Med (Berl)       Date:  1995-05       Impact factor: 4.599

Review 7.  Adrenergic and muscarinic receptor regulation and therapeutic implications in heart failure.

Authors:  W Schmitz; P Boknik; B Linck; F U Müller
Journal:  Mol Cell Biochem       Date:  1996 Apr 12-26       Impact factor: 3.396

8.  Mechanism underlying the reduced positive inotropic effects of the phosphodiesterase III inhibitors pimobendan, adibendan and saterinone in failing as compared to nonfailing human cardiac muscle preparations.

Authors:  H von der Leyen; U Mende; W Meyer; J Neumann; M Nose; W Schmitz; H Scholz; J Starbatty; B Stein; H Wenzlaff
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-07       Impact factor: 3.000

9.  Activator of G protein signaling 3 null mice: I. Unexpected alterations in metabolic and cardiovascular function.

Authors:  Joe B Blumer; Kevin Lord; Thomas L Saunders; Alejandra Pacchioni; Cory Black; Eric Lazartigues; Kurt J Varner; Thomas W Gettys; Stephen M Lanier
Journal:  Endocrinology       Date:  2008-05-01       Impact factor: 4.736

10.  Interruption of signal transduction between G protein and PKC-epsilon underlies the impaired myocardial response to ischemic preconditioning in postinfarct remodeled hearts.

Authors:  Takayuki Miki; Tetsuji Miura; Masaya Tanno; Jun Sakamoto; Atsushi Kuno; Satoshi Genda; Tomoaki Matsumoto; Yoshihiko Ichikawa; Kazuaki Shimamoto
Journal:  Mol Cell Biochem       Date:  2003-05       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.